原发性化疗相对剂量强度降低并不影响霍奇金淋巴瘤患者的预后。

Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma.

作者信息

Raida Ludek, Papajik Tomas, Rusinakova Zuzana, Prochazka Vit, Faber Edgar, Cahova Dana, Tucek Pavel, Indrak Karel

机构信息

Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.

出版信息

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Sep;158(3):428-32. doi: 10.5507/bp.2013.022. Epub 2013 Apr 10.

DOI:10.5507/bp.2013.022

PMID:23579110

Abstract

AIMS

A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment.

METHODS

A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and <90%). Reduced RDI in two groups (90-99% and <90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared.

RESULTS

Multivariate analysis showed here were no significant differences in probability of CR (HR 0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17; HR 1.54, 95% CI [0.91-2.6], P=0.22) or OS (mean 15 vs. 13 vs. 14 years, P=0.13; HR 1.52, 95% CI [0.93-2.5], P=0.13).

CONCLUSION

We found no significant impact of primary chemotherapy delay resulting in reduced RDI on outcome in HL patients.

摘要

目的

对霍奇金淋巴瘤（HL）患者进行回顾性分析，以评估其在初始治疗中接受化疗的相对剂量强度（RDI）的预后情况。

方法

总共194例患者被分为三组，其初始化疗的RDI不同（100%、90 - 99%和<90%）。两组（90 - 99%和<90%）的RDI降低是由于某些化疗疗程给药间隔的延迟所致。对作为患者预后基本参数的完全缓解（CR）概率、疾病复发、无事件生存期（EFS）和总生存期（OS）进行了统计学比较。

结果

多变量分析显示，CR概率（风险比[HR]0.9，95%置信区间[CI][0.75 - 1.08]，P = 0.5）、复发风险（HR 1.34，95% CI[0.92 - 1.94]，P = 0.11）或死亡风险（HR 1.52，95% CI[0.94 - 2.5]，P = 0.13）均无显著差异。EFS概率（平均13年对10年对12年，P = 0.17；HR 1.54，95% CI[0.91 - 2.6]，P = 0.22）或OS（平均15年对13年对14年，P = 0.13；HR 1.52，95% CI[0.93 - 2.5]，P = 0.13）也无显著差异。